Loading...
•
Dec 31, 2020
Castle Biosciences Q4 2020 Earnings Report
Reported a decrease in revenue compared to the same period last year, but maintained a strong gross margin.
Key Takeaways
Castle Biosciences reported Q4 2020 revenues of $17.3 million, a slight decrease from $17.6 million in Q4 2019. The company delivered 5,157 total gene expression profile test reports, compared to 4,914 in the same period in 2019. Gross margin remained strong at 85%.
Revenues were $17.3 million in the fourth quarter of 2020, compared to $17.6 million in the fourth quarter of 2019.
Delivered 5,157 total gene expression profile test reports in the fourth quarter of 2020, compared to 4,914 in the same period in 2019.
Gross margin in the fourth quarter of 2020 was 85%.
Operating cash flow was $(0.4) million in the fourth quarter of 2020, compared to $4.5 million in the fourth quarter of 2019.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...